FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028761750> ?p ?o ?g. }

• W3028761750 abstract "e15583 Background: While immunotherapy has become a pillar of cancer treatment, diagnostic biomarkers that consistently predict patient response to these therapies have remained elusive. There is an increasing need for the development of integrative, composite biomarkers that can model the complex biology driving response and/or resistance to immunotherapy more effectively than existing single-analyte approaches. However, the majority of current cancer diagnostic panels, with their focus on a small set of genes, provide limited ability to support these emerging advanced biomarkers. Methods: To address these limitations, we developed and validated NeXT Dx, a comprehensive enhanced exome and transcriptome based diagnostic platform designed to simultaneously characterize tumor and immune genomics from a single limited FFPE sample. To achieve higher accuracy and sensitivity for an exome scale diagnostic platform, we developed an augmented exome assay that improves uniformity of coverage across all ~20,000 genes, including boosted coverage of 248 clinically-relevant cancer genes. We validated this assay using genomic DNA and RNA extracted from tumor-derived cell-lines, constructs, clinical FFPE samples, and proficiency testing samples. The assay utilizes > = 25ng of co-extracted DNA and RNA which were sequenced using Illumina NovaSeq instruments at our CAP-accredited, CLIA-certified laboratory. Additional assay enhancements for HLA, immune repertoire, and oncoviruses were designed to further optimize the platform for immunotherapy biomarker discovery applications. Results: Validation of NeXT Dx demonstrated a performance of 99.5% sensitivity and 99.8% positive predictive value (PPV) for SNVs with > = 5% AF; 98.7% sensitivity and 97.4% PPV for indels with > = 10% AF; 97.2% sensitivity and 94.6% PPV for CNAs in samples with > = 30% tumor content; 94.9% sensitivity and 94.9% PPV for fusions; and a 2.1% error rate for MSI classification. TMB was calculated using gold-standard whole exome data from SNVs and indels. Typical median coverage depth was > 1,000X for 248 clinically-relevant genes, ~300X for the remaining (whole exome) footprint. Conclusions: With NeXT Dx, we demonstrate a exome/transcriptome scale diagnostic platform that can detect current clinical biomarkers with high sensitivity as well as support emerging, advanced biomarkers that integrate across both tumor and immune features." @default.
• W3028761750 created "2020-06-05" @default.
• W3028761750 creator A5006999733 @default.
• W3028761750 creator A5017647936 @default.
• W3028761750 creator A5026202357 @default.
• W3028761750 creator A5028848325 @default.
• W3028761750 creator A5046200335 @default.
• W3028761750 creator A5048960432 @default.
• W3028761750 creator A5059086243 @default.
• W3028761750 creator A5060089315 @default.
• W3028761750 creator A5067420630 @default.
• W3028761750 creator A5067639383 @default.
• W3028761750 creator A5075177367 @default.
• W3028761750 creator A5085782279 @default.
• W3028761750 date "2020-05-20" @default.
• W3028761750 modified "2023-09-26" @default.
• W3028761750 title "Validation of an exome and transcriptome based diagnostic platform enabling clinical cancer therapy selection and emerging composite biomarkers for immunotherapy." @default.
• W3028761750 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e15583" @default.
• W3028761750 hasPublicationYear "2020" @default.
• W3028761750 type Work @default.
• W3028761750 sameAs 3028761750 @default.
• W3028761750 citedByCount "0" @default.
• W3028761750 crossrefType "journal-article" @default.
• W3028761750 hasAuthorship W3028761750A5006999733 @default.
• W3028761750 hasAuthorship W3028761750A5017647936 @default.
• W3028761750 hasAuthorship W3028761750A5026202357 @default.
• W3028761750 hasAuthorship W3028761750A5028848325 @default.
• W3028761750 hasAuthorship W3028761750A5046200335 @default.
• W3028761750 hasAuthorship W3028761750A5048960432 @default.
• W3028761750 hasAuthorship W3028761750A5059086243 @default.
• W3028761750 hasAuthorship W3028761750A5060089315 @default.
• W3028761750 hasAuthorship W3028761750A5067420630 @default.
• W3028761750 hasAuthorship W3028761750A5067639383 @default.
• W3028761750 hasAuthorship W3028761750A5075177367 @default.
• W3028761750 hasAuthorship W3028761750A5085782279 @default.
• W3028761750 hasConcept C104317684 @default.
• W3028761750 hasConcept C10590036 @default.
• W3028761750 hasConcept C121608353 @default.
• W3028761750 hasConcept C124535831 @default.
• W3028761750 hasConcept C126322002 @default.
• W3028761750 hasConcept C127716648 @default.
• W3028761750 hasConcept C142724271 @default.
• W3028761750 hasConcept C143998085 @default.
• W3028761750 hasConcept C16671776 @default.
• W3028761750 hasConcept C204787440 @default.
• W3028761750 hasConcept C2777701055 @default.
• W3028761750 hasConcept C2780367336 @default.
• W3028761750 hasConcept C2780674031 @default.
• W3028761750 hasConcept C2781197716 @default.
• W3028761750 hasConcept C46111723 @default.
• W3028761750 hasConcept C54355233 @default.
• W3028761750 hasConcept C60644358 @default.
• W3028761750 hasConcept C70721500 @default.
• W3028761750 hasConcept C71924100 @default.
• W3028761750 hasConcept C86803240 @default.
• W3028761750 hasConceptScore W3028761750C104317684 @default.
• W3028761750 hasConceptScore W3028761750C10590036 @default.
• W3028761750 hasConceptScore W3028761750C121608353 @default.
• W3028761750 hasConceptScore W3028761750C124535831 @default.
• W3028761750 hasConceptScore W3028761750C126322002 @default.
• W3028761750 hasConceptScore W3028761750C127716648 @default.
• W3028761750 hasConceptScore W3028761750C142724271 @default.
• W3028761750 hasConceptScore W3028761750C143998085 @default.
• W3028761750 hasConceptScore W3028761750C16671776 @default.
• W3028761750 hasConceptScore W3028761750C204787440 @default.
• W3028761750 hasConceptScore W3028761750C2777701055 @default.
• W3028761750 hasConceptScore W3028761750C2780367336 @default.
• W3028761750 hasConceptScore W3028761750C2780674031 @default.
• W3028761750 hasConceptScore W3028761750C2781197716 @default.
• W3028761750 hasConceptScore W3028761750C46111723 @default.
• W3028761750 hasConceptScore W3028761750C54355233 @default.
• W3028761750 hasConceptScore W3028761750C60644358 @default.
• W3028761750 hasConceptScore W3028761750C70721500 @default.
• W3028761750 hasConceptScore W3028761750C71924100 @default.
• W3028761750 hasConceptScore W3028761750C86803240 @default.
• W3028761750 hasLocation W30287617501 @default.
• W3028761750 hasOpenAccess W3028761750 @default.
• W3028761750 hasPrimaryLocation W30287617501 @default.
• W3028761750 hasRelatedWork W13661531 @default.
• W3028761750 hasRelatedWork W19721952 @default.
• W3028761750 hasRelatedWork W19983576 @default.
• W3028761750 hasRelatedWork W3521414 @default.
• W3028761750 hasRelatedWork W6189649 @default.
• W3028761750 hasRelatedWork W7444607 @default.
• W3028761750 hasRelatedWork W7677563 @default.
• W3028761750 hasRelatedWork W9153885 @default.
• W3028761750 hasRelatedWork W9749177 @default.
• W3028761750 hasRelatedWork W15255855 @default.
• W3028761750 isParatext "false" @default.
• W3028761750 isRetracted "false" @default.
• W3028761750 magId "3028761750" @default.
• W3028761750 workType "article" @default.